LGR6 Inhibitors
LGR6 inhibitors as a chemical class comprise compounds that modulate the activity or expression of LGR6, a G-protein coupled receptor, through indirect mechanisms. These compounds function by perturbing the signaling pathways or cellular processes that govern the activity of LGR6. For example, inhibition of Rho-associated protein kinase (ROCK) by Y-27632 leads to alterations in cytoskeletal dynamics and cell adhesion. Since these cellular processes are foundational for the proper localization and activation of LGR6, Y-27632's actions can attenuate LGR6 signaling indirectly. Similarly, chemicals like LGK-974 and IWP-2 that target Wnt ligand secretion affect the availability of Wnt proteins that bind to receptors like LGR6, thereby modulating its activation state and consequent intracellular signaling cascades.
On the other hand, small molecules such as CHIR99021 and BIO inhibit Glycogen synthase kinase 3 (GSK-3), leading to the stabilization and accumulation of β-catenin in the cytoplasm and its subsequent translocation to the nucleus where it can influence the transcription of Wnt target genes. As LGR6 is part of the complex regulatory circuitry controlled by Wnt/β-catenin signaling, the altered transcriptional landscape caused by GSK-3 inhibitors can affect LGR6 activity. Moreover, inhibitors of pathways such as BMP signaling, like LDN-193189 and Dorsomorphin, have implications for LGR6 modulation due to the interplay between BMP and Wnt signaling pathways. The inhibition of kinases involved in these pathways leads to downstream effects on cellular responses and gene expression patterns, which are critical for the nuanced regulation of LGR6's roles in the cell. The indirect inhibition of LGR6 by these chemical agents is achieved through a multifaceted interplay of signaling alterations, regulatory loop disruptions, and changes in cellular context, emphasizing the intricate nature of intracellular signaling networks and their impact on receptor activity.
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $186.00 $707.00 | 88 | |
A selective inhibitor of ROCK (Rho-associated protein kinase), Y-27632 impedes the Rho/ROCK signaling cascade. This pathway interacts with the cytoskeleton organization affecting LGR6 modulation by altering cell adhesion and motility processes which are essential for the activation and localization of LGR6. | ||||||
GSK-3 Inhibitor IX | 667463-62-9 | sc-202634 sc-202634A sc-202634B | 1 mg 10 mg 50 mg | $58.00 $188.00 $884.00 | 10 | |
GSK-3 Inhibitor IX disrupts the GSK-3-mediated phosphorylation thereby influencing β-catenin stabilization, which is integral to the Wnt signaling pathway. Elevated β-catenin activity can adjust the downstream signaling that indirectly modulates the expression and function of LGR6 by regulating gene transcription. | ||||||
XAV939 | 284028-89-3 | sc-296704 sc-296704A sc-296704B | 1 mg 5 mg 50 mg | $36.00 $117.00 $525.00 | 26 | |
XAV-939 is a Tankyrase inhibitor that stabilizes AXIN by preventing its poly-ADP-ribosylation, consequently augmenting β-catenin destruction complex activity. This action indirectly diminishes Wnt/β-catenin signaling, affecting the cellular milieu in which LGR6 operates, potentially altering its expression or activity due to shifts in gene expression patterns. | ||||||
LGK 974 | 1243244-14-5 | sc-489380 sc-489380A | 5 mg 50 mg | $359.00 $1295.00 | 2 | |
LGK-974 inhibits Porcupine, an O-acyltransferase involved in Wnt ligand secretion and activity. By limiting Wnt ligand availability, LGK-974 indirectly impacts the Wnt/β-catenin signaling pathway, which is associated with the regulation of LGR6, thereby potentially modulating its expression or activity through altered ligand-receptor interactions. | ||||||
IWP-2 | 686770-61-6 | sc-252928 sc-252928A | 5 mg 25 mg | $96.00 $292.00 | 27 | |
Inhibitor of Wnt production-2 (IWP-2) impedes Wnt processing and secretion by inhibiting Porcupine. This leads to reduced Wnt ligand availability for receptor binding, thus affecting the Wnt/β-catenin signaling pathway. The consequent decrease in pathway activity indirectly modulates the regulatory environment of LGR6, which is responsive to Wnt signaling cues. | ||||||
PF-562271 | 717907-75-0 | sc-478488 sc-478488A sc-478488B | 5 mg 10 mg 50 mg | $312.00 $474.00 $1124.00 | 3 | |
PF-562271 is a potent inhibitor of focal adhesion kinase (FAK), which plays a role in cellular adhesion and migration. Inhibition of FAK disrupts integrin signaling and could thereby affect LGR6 activity by modulating cellular contexts such as the extracellular matrix composition and cell-matrix interactions that can influence LGR6 signaling pathways. | ||||||
IWR-1-endo | 1127442-82-3 | sc-295215 sc-295215A | 5 mg 10 mg | $82.00 $135.00 | 19 | |
An inhibitor of Wnt response, IWR-1 destabilizes β-catenin by enhancing the activity of the β-catenin destruction complex. This reduction in β-catenin levels indirectly affects Wnt/β-catenin signaling, leading to potential changes in LGR6 activity due to the modification of the signaling landscape and gene expression profiles influenced by Wnt/β-catenin. | ||||||
4-(6-(4-(Piperazin-1-yl)phenyl)pyrazolo[1,5-a]pyrimidin-3-yl)quinoline | 1062368-24-4 | sc-476297 | 5 mg | $240.00 | ||
A BMP signaling inhibitor that specifically inhibits ALK2 and ALK3 receptors, thereby decreasing SMAD1/5/8 phosphorylation. Given the cross-talk between BMP and Wnt pathways, this can indirectly affect the signaling context of LGR6 by modifying the cellular responses and gene expression patterns related to the interplay of these pathways. | ||||||
Dorsomorphin dihydrochloride | 1219168-18-9 | sc-361173 sc-361173A | 10 mg 50 mg | $186.00 $751.00 | 28 | |
Also known as Compound C, Dorsomorphin inhibits AMPK and BMP signaling, leading to altered phosphorylation states of SMAD proteins. This modulation of BMP signaling indirectly affects the milieu of signaling pathways LGR6 is involved in, potentially altering its activity through the interdependent regulatory mechanisms of these pathways and their downstream effects. | ||||||
GSK-3 Inhibitor XVI | 252917-06-9 | sc-221691 sc-221691A | 5 mg 25 mg | $180.00 $610.00 | 4 | |
GSK-3 Inhibitor XVI increases β-catenin stabilization by preventing GSK-3 mediated β-catenin phosphorylation and degradation. This elevation of β-catenin activity indirectly influences LGR6 by altering the gene expression environment within the cell due to enhanced Wnt/β-catenin signaling, thus potentially modulating LGR6 expression and function. | ||||||